Site-Specific Protein Conjugation via Modified Amino Acid Residues
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The production of chemically altered protein therapeutics faces challenges in achieving biologically active, homogenous forms due to difficulties in controlling the conjugation of drugs or labels to proteins, resulting in heterogeneous mixtures with varying drug attachment numbers and conjugation sites.
Innovation Solution
The development of specific conjugate structures and production methods involving modified amino acid residues and compounds that allow precise and selective formation of chemical bonds between polypeptides and drugs or detectable labels, using reactive groups like aldehyde or ketone groups under controlled reaction conditions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If standard chemical transformations are used to modify amino acid side chains, then chemical conjugation can be achieved, but heterogeneous mixtures are produced with varying drug attachment numbers and conjugation sites
Solution Approach 1:
The patent introduces site-specific modification by targeting particular amino acid residues (such as lysine or cysteine) within the polypeptide chain. By designing modified amino acid residues with unique reactive groups at specific positions, the conjugation occurs locally at predetermined sites rather than randomly throughout the protein, thereby achieving homogeneous conjugates with controlled drug attachment numbers and positions.
2Productivity
If chemical conjugation is performed without site-specific control, then drug attachment can occur, but the resulting mixture lacks biological activity consistency
Solution Approach 1:
The patent employs preliminary action by first incorporating modified amino acid residues with predetermined reactive groups into the polypeptide chain before conjugation. These pre-installed reactive groups (such as aldehydes, ketones, or other electrophilic groups) are positioned at specific sites to guide subsequent drug attachment. This preliminary preparation ensures that conjugation occurs at controlled locations, maintaining biological activity consistency while achieving efficient drug attachment.
3Adaptability or versatility
If multiple reactive groups are used for conjugation, then conjugation flexibility increases, but control over conjugation site and drug number decreases
Solution Approach 1:
The patent uses modified amino acid residues as intermediary structures that contain specific reactive groups designed to react selectively with corresponding groups on the drug molecule. These intermediary modified residues act as controlled docking sites, providing both flexibility in choosing different reactive group types (aldehydes, ketones, epoxides, etc.) and precision in controlling where and how many drugs attach to the polypeptide chain.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enables the production of stable, biologically active protein conjugates with controlled drug or label attachment, enhancing their therapeutic efficacy and specificity while minimizing side effects.
Implementation Method 1
The disclosure also encompasses methods of production of such conjugates, as well as methods of using the same. Embodiments of the present disclosure include a conjugate that includes at least one modified amino acid residue... wherein one of W1 and W2 is a polypeptide and the other is a drug or a detectable label
Data Source
AI summary
The present disclosure provides conjugate structures and compound structures used to produce these conjugates. The disclosure also encompasses methods of production of such conjugates, as well as methods of using the same.